Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer (HR+HER2-)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Temporarily pausedNCT05503108
What this trial is testing

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Who this might be right for
Fasting Mimicking DietHER2-negative Breast CancerHormone Receptor-positive Breast Cancer+3 more
Leiden University Medical Center 10
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Ended earlyNCT01147016
What this trial is testing

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 8
Not applicableLooking for participantsNCT07702708
What this trial is testing

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Breast CancerBreast Neoplasms
Fujian Cancer Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT04577963
What this trial is testing

Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Triple Negative Breast CancerEndometrial CancerSolid Tumor, Unspecified, Adult+1 more
Hutchmed 52
Large-scale testing (Phase 3)Not Yet RecruitingNCT07340658
What this trial is testing

Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories 300
Testing effectiveness (Phase 2)Study completedNCT05969184
What this trial is testing

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Who this might be right for
Breast Neoplasm Female
Peking University Cancer Hospital & Institute 94
Testing effectiveness (Phase 2)UnknownNCT04941885
What this trial is testing

Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 78
Not applicableStudy completedNCT04671615
What this trial is testing

Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Who this might be right for
Metastatic Breast Cancer
Pfizer 559
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Large-scale testing (Phase 3)Active Not RecruitingNCT06764186
What this trial is testing

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
AstraZeneca 101
Not applicableStudy completedNCT04992156
What this trial is testing

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Who this might be right for
Metastatic Breast Cancer
Fudan University 50
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Not applicableLooking for participantsNCT07476170
What this trial is testing

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

Who this might be right for
HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 14,000
Large-scale testing (Phase 3)UnknownNCT03927456
What this trial is testing

SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 357
Not applicableStudy completedNCT05770713
What this trial is testing

A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.

Who this might be right for
Breast Cancer
Pfizer 48
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Testing effectiveness (Phase 2)Looking for participantsNCT07180160
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 123
Large-scale testing (Phase 3)Active Not RecruitingNCT05077449
What this trial is testing

XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 300
Next Page